Stockscreener 앱 받기
1.19
5.56%
-0.07
시간 외 거래:
1.21
0.02
+1.68%
전일 마감가:
$1.26
열려 있는:
$1.24
하루 거래량:
1.98M
Relative Volume:
0.94
시가총액:
$137.24M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.7212
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
-20.13%
1개월 성능:
-1.65%
6개월 성능:
-9.16%
1년 성능:
-56.88%
1일 변동 폭
$1.185
$1.3082
1주일 범위
$1.185
$1.505
52주 변동 폭
$0.6611
$3.50
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.19 | 145.32M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Why Fate Therapeutics Inc. stock remains a top recommendationJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - sharewise.com
How Fate Therapeutics Inc. stock benefits from global expansion2025 Technical Overview & Fast Momentum Entry Tips - newser.com
How to use a screener to detect Fate Therapeutics Inc. breakoutsJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Why Fate Therapeutics Inc. stock is a value investor pickJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com
Will Fate Therapeutics Inc. see short term momentumJuly 2025 Sector Moves & Verified Short-Term Plans - newser.com
What Fibonacci levels say about Fate Therapeutics Inc. reboundWeekly Trade Report & Capital Efficient Trading Techniques - newser.com
How resilient is Fate Therapeutics Inc. stock in market downturnsVolume Spike & Technical Confirmation Trade Alerts - newser.com
Can trapped investors hope for a rebound in Fate Therapeutics Inc.Weekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Developing predictive dashboards with Fate Therapeutics Inc. dataWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Q3 Earnings Estimate for FATE Issued By HC Wainwright - MarketBeat
Analyzing drawdowns of Fate Therapeutics Inc. with statistical toolsWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Multi factor analysis applied to Fate Therapeutics Inc.Earnings Growth Summary & Entry Point Strategy Guides - newser.com
Automated trading signals detected on Fate Therapeutics Inc.2025 Analyst Calls & AI Driven Stock Reports - newser.com
Will Fate Therapeutics Inc. stock recover faster than marketAnalyst Upgrade & Smart Investment Allocation Insights - newser.com
Is Fate Therapeutics Inc. stock undervalued vs historical averagesSell Signal & Free Safe Entry Trade Signal Reports - newser.com
How sentiment analysis helps forecast Fate Therapeutics Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Fate Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
HC Wainwright & Co. Upgrades Fate Therapeutics (FATE) - Nasdaq
HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target - MarketScreener
Q3 Earnings Forecast for Fate Therapeutics Issued By Wedbush - MarketBeat
What drives Fate Therapeutics Inc stock priceVolume Weighted Average Price & Low Cost Trading Plans - earlytimes.in
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):